Key facts
- This page summarizes Michael Secora's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
- 1 reported transaction and 6 derivative rows are listed below.
- Accepted by SEC: 19 Nov 2024, 18:26.
Michael Secora - 15 Nov 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- RXRX
- Reported as of
- 15 Nov 2024
- Net transaction value
- -$73,711
- SEC form
- 4
- Accepted by SEC
- 19 Nov 2024, 18:26:27 UTC
- Prior SEC filing
- 14 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/Jonathan Golightly, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Secora filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 19 Nov 2024.
Change
- Previous filing in this sequence was filed on 14 Nov 2024.
- Current net transaction value: -$73,711.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RXRX
transaction
Class A Common Stock
Tax liability
- Transaction value
- $73,711
- Shares
- -11,937
- Change %
- -0.8%
- Price
- $6.18
- Shares after
- 1,487,694
- Date
- 15 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 337,635
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $2.22
- Footnotes
- F2
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 685,177
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $2.22
- Footnotes
- F3
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,914
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $11.40
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 116,684
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $11.40
- Footnotes
- F4
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 404,857
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $8.55
- Footnotes
- F5
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 348,380
- Date
- 15 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $10.09
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
Footnote F2
The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
Footnote F3
The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
Footnote F4
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Footnote F5
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Footnote F6
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.